Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Pneumonia Therapeutics Market: By Therapeutics, By Distribution Channel, By Age Group, and Geography
Pneumonia Therapeutics Market: By Therapeutics, By Distribution Channel, By Age Group, and Geography
Pneumonia Therapeutics Market size was valued at US$ 14,956.4 million in 2023 and is poised to grow at a CAGR of 8.7% from 2024-2030. Pneumonia is an inflammatory medical disorder that disturbs the alveoli and air sacs in the lungs. Pathogens such as viruses, bacteria, and fungi are the leading cause of pneumococcal infection using inhalation of air-borne droplets from coughing or sneezing. Pneumonia can also happen through contact with surfaces and objects that are soiled with pneumonia-causing viruses and bacteria.
According to the kind of case, the medicines are to be given. For example, if pneumonia is produced by bacteria, an antibiotic is prescribed. Pneumonia therapeutics comprise the approaches such as drugs and vaccinations that can support managing of the infection. The infection can be severe but are predominantly lethal to children, infants, and individuals over 65. The rising prevalence of pneumococcal disease can lead to the growth of the pneumonia therapeutics market.
Moreover, the growing pollution level in the environment, the introduction of preventive vaccination programs, and improved standards introduced by healthcare facilities over the market are some primary factors that can boost the global pneumonia therapeutics market share. Apart from these, the increased prevalence rate of lung illnesses worldwide can also accelerate the market in the future. However, some factors, such as the absence of patient awareness and restricted access to therapy, may restrain the growth of the market. The current clinical trials for the expansion of vaccine and drug molecules can create an opportunity for the growth of the global pneumonia therapeutics market.
Study Period
2024-2030Base Year
2023CAGR
8.7%Largest Market
Asia PacificFastest Growing Market
North America
One of the major reasons for the growth of the global pneumonia therapeutics market is the growing funding for the development of the new product to report disease management. The high brutality of pneumonia, together with high demand from the market, is expected to propel the growth of the market in the forecast period. For example, in the current scenario, various companies working in the pneumonia therapeutics market, which comprises market giants like Merck, Pfizer, and GSK, are maneuvering huge capital and putting massive efforts into such research and development activities. This is further enhanced by positive clinical trials and regulatory approvals from concerned authorities.
North America is dominating the global pneumonia therapeutics market due to the growing geriatric population and growing multidrug resistance in children and adults, repeats the demand for the development of advanced-generation therapeutics. Moreover, global market players are capitalizing more on research and development and concentrating on new product development actions, which have also contributed to the growth of the market. However, numerous government initiatives intended for the treatment and prevention of pneumonia are accountable for generating a positive influence across North America.
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
Report Study Period |
2024-2030 |
|
Market Size in 2023 |
US$ 14,956.4 million |
|
Market CAGR |
8.7% |
|
By Therapeutics |
|
|
By Distribution Channel |
|
|
By Age Group |
|
Download Free Sample Report
The pneumonia therapeutics market size was valued at US$ 14,956.4 million in 2023 and is expected to grow at a significant CAGR of 8.7% from 2024 to 2030.
The current clinical trials for the expansion of vaccine and drug molecules can create an opportunity for the growth of the global pneumonia therapeutics market.
In September 2022, FDA approved Nabriva Therapeutics’ Xenleta (lefamulin) to treat community-acquired bacterial pneumonia (CABP) as the first in a new class of antibiotics called pleuromutilins, which target a different protein synthesis binding site than older competitors.
| 1. Executive Summary |
| 2. Global Pneumonia Therapeutics Market Introduction |
| 2.1. Global Pneumonia Therapeutics Market – Taxonomy |
| 2.2. Global Pneumonia Therapeutics Market – Definitions |
| 2.2.1. Therapeutics |
| 2.2.2. Distribution Channel |
| 2.2.3. Age Group |
| 2.2.4. By Region |
| 3. Global Pneumonia Therapeutics Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Global Pneumonia Therapeutics Market Dynamic Factors - Impact Analysis |
| 3.6. Global Pneumonia Therapeutics Market – Competition Landscape |
| 4. Global Pneumonia Therapeutics Market, By Therapeutics, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 4.1. Prevention Vaccines |
| 4.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 4.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 4.1.3. Market Opportunity Analysis |
| 4.2. Treatment Drugs |
| 4.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 4.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 4.2.3. Market Opportunity Analysis |
| 5. Global Pneumonia Therapeutics Market, By Distribution Channel, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.1. Hospitals |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Pharmaceutical Stores |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Others |
| 5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 6. Global Pneumonia Therapeutics Market, By Age Group, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 6.1. Pediatric |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Adult |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Geriatric |
| 6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 7. Global Pneumonia Therapeutics Market Forecast, By Region, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 7.1. North America |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Europe |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Asia-Pacific |
| 7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Latin America |
| 7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 7.5. Middle East and Africa |
| 7.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.5.3. Market Opportunity Analysis |
| 7.6. Global Pneumonia Therapeutics Market - Opportunity Analysis Index, By Therapeutics, By Distribution Channel, By Age Group, and Region, 2024 - 2030 |
| 8. North America Pneumonia Therapeutics Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 8.1. Therapeutics Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 8.1.1. Prevention Vaccines |
| 8.1.2. Treatment Drugs |
| 8.2. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 8.2.1. Hospitals |
| 8.2.2. Pharmaceutical Stores |
| 8.2.3. Others |
| 8.3. Age Group Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 8.3.1. Pediatric |
| 8.3.2. Adult |
| 8.3.3. Geriatric |
| 8.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 8.4.1. USA |
| 8.4.2. Canada |
| 8.5. North America Pneumonia Therapeutics Market - Opportunity Analysis Index, By Therapeutics, By Distribution Channel, By Age Group, and Country, 2024 - 2030 |
| 8.6. North America Pneumonia Therapeutics Market Dynamics – Trends |
| 9. Europe Pneumonia Therapeutics Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 9.1. Therapeutics Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1. Prevention Vaccines |
| 9.1.2. Treatment Drugs |
| 9.2. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1. Hospitals |
| 9.2.2. Pharmaceutical Stores |
| 9.2.3. Others |
| 9.3. Age Group Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1. Pediatric |
| 9.3.2. Adult |
| 9.3.3. Geriatric |
| 9.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 9.4.1. Germany |
| 9.4.2. UK |
| 9.4.3. France |
| 9.4.4. Spain |
| 9.4.5. Italy |
| 9.4.6. Rest of Europe |
| 9.5. Europe Pneumonia Therapeutics Market - Opportunity Analysis Index, By Therapeutics, By Distribution Channel, By Age Group, and Country, 2024 - 2030 |
| 9.6. Europe Pneumonia Therapeutics Market Dynamics – Trends |
| 10. Asia-Pacific Pneumonia Therapeutics Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 10.1. Therapeutics Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1. Prevention Vaccines |
| 10.1.2. Treatment Drugs |
| 10.2. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1. Hospitals |
| 10.2.2. Pharmaceutical Stores |
| 10.2.3. Others |
| 10.3. Age Group Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1. Pediatric |
| 10.3.2. Adult |
| 10.3.3. Geriatric |
| 10.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 10.4.1. China |
| 10.4.2. India |
| 10.4.3. Japan |
| 10.4.4. ASEAN |
| 10.4.5. Australia & New Zealand |
| 10.4.6. Rest of Asia-Pacific |
| 10.5. Asia-Pacific Pneumonia Therapeutics Market - Opportunity Analysis Index, By Therapeutics, By Distribution Channel, By Age Group, and Country, 2024 - 2030 |
| 10.6. Asia-Pacific Pneumonia Therapeutics Market Dynamics – Trends |
| 11. Latin America Pneumonia Therapeutics Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 11.1. Therapeutics Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1. Prevention Vaccines |
| 11.1.2. Treatment Drugs |
| 11.2. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1. Hospitals |
| 11.2.2. Pharmaceutical Stores |
| 11.2.3. Others |
| 11.3. Age Group Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1. Pediatric |
| 11.3.2. Adult |
| 11.3.3. Geriatric |
| 11.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 11.4.1. Brazil |
| 11.4.2. Mexico |
| 11.4.3. Rest of Latin America |
| 11.5. Latin America Pneumonia Therapeutics Market - Opportunity Analysis Index, By Therapeutics, By Distribution Channel, By Age Group, and Country, 2024 - 2030 |
| 11.6. Latin America Pneumonia Therapeutics Market Dynamics – Trends |
| 12. Middle East and Africa Pneumonia Therapeutics Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 12.1. Therapeutics Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1. Prevention Vaccines |
| 12.1.2. Treatment Drugs |
| 12.2. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1. Hospitals |
| 12.2.2. Pharmaceutical Stores |
| 12.2.3. Others |
| 12.3. Age Group Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1. Pediatric |
| 12.3.2. Adult |
| 12.3.3. Geriatric |
| 12.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 12.4.1. Gulf Cooperation Council (GCC) Countries |
| 12.4.2. South Africa |
| 12.4.3. Rest of MEA |
| 12.5. MEA Pneumonia Therapeutics Market- Opportunity Analysis Index, By Therapeutics, By Distribution Channel, By Age Group, and Country, 2024 - 2030 |
| 12.6. MEA Pneumonia Therapeutics Market Dynamics – Trends |
| 13. Competition Landscape |
| 13.1. Strategic Dashboard of Top Market Players |
| 13.2. Company Profiles (Introduction, Financial Analysis, Key Therapeuticss, Key Developments, Strategies, and SWOT Analysis) |
| 13.2.1. Abbott Laboratories |
| 13.2.2. Allergan |
| 13.2.3. AstraZeneca |
| 13.2.4. Bayer |
| 13.2.5. Cipla |
| 13.2.6. GlaxoSmithKline Plc. |
| 13.2.7. Lupin Pharmaceuticals Ltd. |
| 13.2.8. Merck |
| 13.2.9. Mylan |
| 13.2.10. Novartis AG |
| 13.2.11. Pfizer, Inc. |
| 14. Research Methodology |
| 15. Key Assumptions and Acronyms |
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.